



Mouse Anti-Obinutuzumab monoclonal antibody, clone 29I9 (CABT-ZB219)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Specificity	The product is specific for Obinutuzumab.
Target	Obinutuzumab
Immunogen	Obinutuzumab
Isotype	IgG1, κ
Source/Host	Mouse
Clone	29I9
Purification	Protein A purified
Conjugate	Unconjugated
Applications	Suitable for use in PK bridging ELISA. We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB219 - CABT-ZB220; CABT-ZB219 - CABT-ZB221 Recommended Working Concentration: 0.005-1 µg/ml
Reconstitution	Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Format	Purified, Lyophilized.
Size	40 µg
Buffer	Lyophilized with PBS, pH 7.4, contains 0.02% sodium azide.
Preservative	0.02% sodium azide

Storage	The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.
Ship	Wet ice

BACKGROUND

Introduction	Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naïve patients, and as a second line treatment for follicular lymphoma. Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.
Keywords	Mouse monoclonal antibody to Gazyva; Afutuzumab; Obinutuzumab; GA 101

GENE INFORMATION

Synonyms	Mouse monoclonal antibody to Gazyva; Afutuzumab; Obinutuzumab; GA 101
-----------------	---